Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.
Risk and Volatility
Ernexa Therapeutics has a beta of 5.62, indicating that its stock price is 462% more volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.6, indicating that its stock price is 160% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Ernexa Therapeutics and Telomir Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ernexa Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Telomir Pharmaceuticals | 1 | 0 | 1 | 1 | 2.67 |
Valuation and Earnings
This table compares Ernexa Therapeutics and Telomir Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ernexa Therapeutics | $580,000.00 | 16.40 | -$44.54 million | ($8.31) | -0.15 |
| Telomir Pharmaceuticals | N/A | N/A | -$16.53 million | ($0.54) | -2.78 |
Telomir Pharmaceuticals has lower revenue, but higher earnings than Ernexa Therapeutics. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Ernexa Therapeutics and Telomir Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ernexa Therapeutics | N/A | N/A | -682.08% |
| Telomir Pharmaceuticals | N/A | -4,595.08% | -1,750.91% |
Insider & Institutional Ownership
70.6% of Ernexa Therapeutics shares are owned by institutional investors. 1.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Ernexa Therapeutics beats Telomir Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
